p8 Inhibitors
The class of p8 inhibitors comprises a collection of chemicals strategically designed to modulate p8 activity through the inhibition of key components within the NF-κB signaling pathway. Central to this category is the inhibition of NF-κB activation, a pivotal regulator of p8 expression. Noteworthy among these inhibitors is BAY 11-7082, which directly targets NF-κB, inhibiting its translocation to the nucleus and subsequently downregulating p8 transcription. Several inhibitors, such as TPCA-1 and Parthenolide, specifically target IKK-2, a kinase crucial in the NF-κB pathway, leading to the inhibition of NF-κB activation and, consequently, the modulation of p8 expression. These compounds showcase the intricate interplay within the NF-κB signaling cascade and provide insights into strategies for controlling p8-associated cellular processes.
JSH-23 and IMD 0354 represent inhibitors that focus on disrupting NF-κB translocation, showcasing alternative points of intervention within the NF-κB pathway. These compounds indirectly influence p8 expression, demonstrating the diverse mechanisms by which NF-κB-related pathways can be modulated to impact p8-associated cellular functions. The broader category includes compounds like Wedelolactone, CAPE, Andrographolide, and Luteolin, all of which inhibit NF-κB activation by interfering with the phosphorylation and degradation of IκB. These compounds collectively emphasize the significance of targeted interventions in the NF-κB pathway for controlling p8 expression and influencing associated cellular processes. In summary, the class of p8 inhibitors offers a sophisticated toolkit for researchers to explore and manipulate the NF-κB signaling pathway, providing valuable insights into the regulatory mechanisms governing p8 activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB activation. By preventing the phosphorylation and subsequent degradation of IκB, it hinders the translocation of NF-κB to the nucleus, thereby downregulating the transcription of p8. The inhibition of NF-κB activation directly modulates the expression of p8, influencing its cellular functions and associated pathways. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
IKK-2 Inhibitor IV, TPCA-1, is a selective inhibitor of IKK-2, a crucial kinase in the NF-κB signaling pathway. By targeting IKK-2, TPCA-1 impedes the phosphorylation and degradation of IκB, inhibiting NF-κB activation. This inhibition indirectly suppresses p8 expression as it is downstream of NF-κB, revealing a potential avenue for p8 modulation through the targeted inhibition of specific components within the NF-κB signaling cascade. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide is an inhibitor of IκB kinase, preventing the phosphorylation and subsequent degradation of IκB. By blocking this step in the NF-κB pathway, parthenolide interferes with NF-κB translocation to the nucleus, thereby modulating the transcription of p8. This direct inhibition of the NF-κB signaling pathway serves as a regulatory mechanism influencing p8 expression and associated cellular processes. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
Also called JSH-23, this compound is an inhibitor of NF-κB translocation by preventing the nuclear import of p65. By interfering with this key step in the NF-κB pathway, JSH-23 indirectly downregulates the transcription of p8. The inhibition of NF-κB translocation showcases a specific point of intervention in regulating p8 expression, emphasizing the potential impact of modulating NF-κB-related pathways on p8-associated cellular functions. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IMD 0354 is an inhibitor of IKK-2, a critical kinase in the NF-κB signaling pathway. By targeting IKK-2, IMD 0354 inhibits the phosphorylation and degradation of IκB, leading to the suppression of NF-κB activation. The indirect inhibition of p8 occurs as a downstream effect of NF-κB modulation, revealing a potential avenue for controlling p8 expression through targeted interventions in the NF-κB signaling cascade. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $110.00 $337.00 | 8 | |
Wedelolactone is an inhibitor of IKK-2, a kinase involved in the NF-κB signaling pathway. By impeding the phosphorylation and degradation of IκB, wedelolactone inhibits NF-κB activation, indirectly influencing the transcription of p8. This targeted intervention in the NF-κB pathway highlights a mechanism for modulating p8 expression, providing insights into potential strategies for controlling p8-associated cellular processes. | ||||||
Caffeic acid phenethyl ester | 104594-70-9 | sc-200800 sc-200800A sc-200800B | 20 mg 100 mg 1 g | $71.00 $296.00 $612.00 | 19 | |
CAPE is an inhibitor of NF-κB activation by suppressing the phosphorylation and degradation of IκB. By blocking this key step in the NF-κB signaling pathway, CAPE hinders the translocation of NF-κB to the nucleus, leading to the downregulation of p8 transcription. The direct inhibition of NF-κB activation showcases a mechanism for controlling p8 expression and influencing associated cellular processes through targeted interventions in the NF-κB signaling cascade. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
Andrographolide is an inhibitor of NF-κB activation by preventing the phosphorylation and degradation of IκB. Through this action, it disrupts NF-κB translocation to the nucleus, indirectly modulating the transcription of p8. This targeted intervention in the NF-κB pathway provides insights into potential strategies for controlling p8 expression and influencing associated cellular processes. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 is a selective inhibitor of IKK-1, a kinase in the NF-κB signaling pathway. By targeting IKK-1, BMS-345541 inhibits the phosphorylation and degradation of IκB, leading to the suppression of NF-κB activation. The indirect inhibition of p8 occurs as a downstream effect of NF-κB modulation, revealing a potential avenue for controlling p8 expression through targeted interventions in the NF-κB signaling cascade. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $27.00 $51.00 $101.00 $153.00 $1925.00 | 40 | |
Luteolin is an inhibitor of NF-κB activation by preventing the phosphorylation and degradation of IκB. Through this mechanism, it impedes NF-κB translocation to the nucleus, indirectly influencing the transcription of p8. This targeted intervention in the NF-κB pathway provides insights into potential strategies for controlling p8 expression and influencing associated cellular processes. | ||||||